Sugi Predict

Sugi Predict / Compounds / SCHEMBL897326

SCHEMBL897326

SCHEMBL897326

C#Cc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 20/20 0.85
▸ KDR P35968 4/20 0.82
▸ KIT P10721 3/20 0.82
▸ GAK O14976 1/20 0.80
▸ ACOX3 O15254 1/20 0.80
▸ NR1I2 O75469 1/20 0.80
▸ ABCB11 O95342 1/20 0.80
▸ EGFR P00533 1/20 0.80
▸ ESR1 P03372 1/20 0.80
▸ PGR P06401 1/20 0.80
▸ RET P07949 1/20 0.80
▸ ROS1 P08922 1/20 0.80
▸ ADORA3 P0DMS8 1/20 0.80
▸ PHKG2 P15735 1/20 0.80
▸ FER P16591 1/20 0.80
▸ EPHA1 P21709 1/20 0.80
▸ DRD1 P21728 1/20 0.80
▸ SLC6A2 P23975 1/20 0.80
▸ PDE4A P27815 1/20 0.80
▸ SLC6A4 P31645 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29895702 1.00 ALK (0.85) ALKKDRKITGAKACOX3
SCHEMBL27087532 0.94 ALK (0.77) ALKKDRKITGAKACOX3
SCHEMBL897292 0.93 ALK (0.88) ALKKDRKITGAKACOX3
SCHEMBL897286 0.92 ALK (1.00) ALKKDRKITGAKACOX3
SCHEMBL897118 0.92 ALK (0.84) ALKKDRKITGAKACOX3
SCHEMBL897457 0.91 ALK (0.94) ALKKDRKIT
SCHEMBL22066145 0.91 ALK (0.80) ALKKDRKITGAKACOX3
SCHEMBL21499487 0.90 ALK (0.78) ALKKDRKITGAKACOX3
SCHEMBL898079 0.90 ALK (0.84) ALKKDRKITGAKACOX3
SCHEMBL896881 0.90 ALK (1.00) ALKKDRKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114327-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-04-10 — — US disclosed
US-20230398096-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-12-14 — — US disclosed
US-20230398096-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-12-14 — — US disclosed
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 — — US disclosed
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 — — US disclosed
CN-110891947-B Process for preparing ailutinib or a pharmaceutically acceptable salt thereof 北京费森尤斯卡比医药有限公司 2022-11-25 — — CN disclosed
US-11465999-B2 Process for preparing Alectinib or a pharmaceutically acceptable salt thereof FRESENIUS KABI ONCOLOGY LTD. (IN) 2022-10-11 — — US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 — — US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 — — US disclosed
US-20220009917-A1 PROCESS FOR THE PREPARATION OF ALECTINIB Fresenius Kabi Ipsum S.R.L. (IT) 2022-01-13 — — US disclosed
US-9126931-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-09-08 — — US disclosed
US-20150150845-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 — — US disclosed
US-20150150845-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 — — US disclosed
EP-2606886-A1 COMPOSITION CONTAINING TETRACYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2013-06-26 — — EP disclosed
EP-2606886-A1 COMPOSITION CONTAINING TETRACYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2013-06-26 — — EP disclosed
US-20130143877-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2013-06-06 — — US disclosed
US-20130143877-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2013-06-06 — — US disclosed
EP-2441753-A1 TETRACYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2012-04-18 — — EP disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 — — US disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143877-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND ALK, ALPI, TTR ALK 1/4885KDR 71/4885KIT 250/4885
US-20230142119-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 ALK 1/4885KDR 167/4885KIT 378/4885
US-20250114327-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND ALK, ALPI, TTR ALK 1/4885KDR 71/4885KIT 250/4885
US-20120083488-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 ALK 1/4885KDR 167/4885KIT 378/4885
US-20220306578-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 ALK 1/4885KDR 167/4885KIT 378/4885
US-20230398096-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND ALK, ALPI, TTR ALK 1/4885KDR 71/4885KIT 250/4885
US-20220009917-A1 PROCESS FOR THE PREPARATION OF ALECTINIB FIP1L1, PLEC, FCGRT ALK 26/4885KDR 1098/4885KIT 920/4885
US-11465999-B2 Process for preparing Alectinib or a pharmaceutically acceptable salt thereof PLEC, SF3B5, FCGR3B ALK 78/4885KDR 1642/4885KIT 652/4885
US-20150150845-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 ALK 1/4885KDR 167/4885KIT 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.